8530498

Celgene sued Zydus/Cadila/Zydus International for patent infringement under 35 U.S.C. § 271(e)(2) in D.N.J. The case asserted multiple lenalidomide patents including 8,648,095. Consent judgment entered 2021-03-24 dismissing with prejudice pursuant to settlement.

Patent infringement action involving ANDA No. 209348; complaint expressly alleged infringement of the '800, '217, '569, '498, '095, '621 and '622 patents. Settled September 17, 2020 with volume-limited license from September 1, 2022 and unlimited from January 31, 2026.

Antitrust/pay-for-delay litigation challenging Revlimid generic settlements. Patents cited include the Revlimid patent family; on September 29, 2026, the court denied motions to dismiss, finding a plausible pay-for-delay agreement between Celgene and Natco.

Antitrust action against Celgene concerning Revlimid settlements; patents cited include the same Revlimid patent set as the In re Revlimid litigation.

Antitrust action by Blue Cross Blue Shield Association plaintiffs against Celgene/BMS concerning Revlimid settlements; patents cited include the same Revlimid patent set as the In re Revlimid litigation.

Part of the Natco lenalidomide litigation family; resolved via the Natco settlement in Dec. 2015. Parties for this docket were inferred and not independently confirmed.

Celgene sued Lotus/Alvogen; the case was terminated after a March 2019 settlement providing volume-limited entry after March 2022. The '498 patent was among the listed patents.

Consent judgment entered July 21/23, 2021, enjoining Mylan from infringing the Patents-in-Suit, including the '498 patent, until expiration and dismissing all claims with prejudice.

Cipla filed an Answer regarding ANDA No. 214618 for 2.5 mg Revlimid. The '498 patent was among the patents-in-suit per Cipla's answer.

Hikma answered and counterclaimed on June 22, 2021; the case was later resolved via settlement, with Hikma listed among later-filing generics settling with Celgene. The '498 patent was asserted.

Antitrust action under the Clayton Act, 15:25, in which the '498 patent is a subject. The case was terminated on 2021-04-18.

Antitrust litigation in which the '498 patent is a subject. The case was terminated on 2020-12-02 and noted as consolidated/transferred with a 'DO NOT DOCKET' notation.